Merck & Co. has added another experimental vaccine to its pipeline, paying $50 million to Opko Health for a preclinical candidate aimed at the Epstein-Barr virus, which causes mononucleosis and is linked to multiple sclerosis and some types of cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,